Tulane University Awarded Contract Up to $16 Million to Bring Pneumonia Nasal Vaccine to Clinical Trials
April 08, 2023
April 08, 2023
NEW ORLEANS, Louisiana, April 8 (TNSfund) -- Tulane University issued the following news release:
The National Institute of Allergy and Infectious Diseases awarded a contract worth up to $16 million to Tulane University to bring a nasal spray pneumonia vaccine to Phase One clinical trial. University researchers invented the experimental vaccine to thwart antibiotic-resistant Klebsiella pneumoniae, a leading cause of bacterial pneumonia.
Antibiotic-resistant bacteria are . . .
The National Institute of Allergy and Infectious Diseases awarded a contract worth up to $16 million to Tulane University to bring a nasal spray pneumonia vaccine to Phase One clinical trial. University researchers invented the experimental vaccine to thwart antibiotic-resistant Klebsiella pneumoniae, a leading cause of bacterial pneumonia.
Antibiotic-resistant bacteria are . . .